Cantabio Pharmaceuticals, Inc.

Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company with a mission to slow, stop and even prevent the onset and progression of neurodegenerative diseases. Founded in 2009, the company focuses on commercializing novel therapies and intellectual property to combat Parkinson’s disease (PD), Alzheimer’s disease (AD), and other related neurodegenerative diseases. Its innovative strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology to develop small molecule pharmacological chaperones for clinical trials. Additionally, Cantabio is working on the development of therapeutic proteins that can cross the blood-brain barrier to supplement existing levels of proteins displaying loss of function during disease conditions. Recently, the company secured a grant investment from The Michael J. Fox Foundation for Parkinson's Research, demonstrating its potential and attracting attention from prominent investors. Cantabio's steadfast dedication to addressing critical unmet medical needs makes it an intriguing prospect for future developments in the biotechnology and pharmaceutical sectors.